Denali: Denali Initiates BLA Filing For Accelerated Approval Of Hunter Syndrome Treatment
(RTTNews) - Denali Therapeutics Inc. (DNLI), Wednesday announced that the company's initiation of a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II) has been received by the Cen
Read full article »
Denali is a California-based biotechnology company that develops molecular therapeutics for the treatment of neurodegenerative diseases.
Read more